Abbott Laboratories (ABT) announced its most recent quarterly financial results on Wednesday, Oct-19-2016. ABT said it had a profit of $0.59 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $0.58. The company posted revenue of $5302.00 million in the period, compared to analysts expectations of $5288.92 million. ABT’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.54 EPS.
Abbott Laboratories closed down -0.19 points or -0.46% at $40.79 with 88,18,965 shares getting traded on Friday. Post opening the session at $41.17, the shares hit an intraday low of $40.77 and an intraday high of $41.53 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Sep 28, 2016, Daniel Gesua Sive Salvadori (Senior Vice President) sold 815 shares at $41.71 per share price. According to the SEC, on Jul 29, 2016, Stephen R Fussell (Executive Vice President) sold 41,500 shares at $45.01 per share price. On Jul 27, 2016, Robert E Funck (Vice President, Controller) sold 26,800 shares at $43.08 per share price, according to the Form-4 filing with the securities and exchange commission.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.